Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders

Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders

US Patent 7423149 · Granted Sep 9, 2008

Estimated economic value: $72,239,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Cyclic di-nucleotide compounds as sting agonists2023
Compounds, compositions and methods of use2023
Cyclic di-nucleotide compounds as sting agonists2022
Carbamate and urea compounds as multikinase inhibitors2022
Cyclic compounds as immunomodulating agents2021
Macrocyclic compounds as TRK kinase inhibitors and uses thereof2021
C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as2021
C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker as2020
Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic ace2019
Compound useful for altering the levels of bile acids for the treatment of diabe2019
Compounds useful for altering the levels of bile acids for the treatment of diab2019
Compounds useful for altering the levels of bile acids for the treatment of diab2019